Stone House Investment Management’s AbCellera Biologics ABCL Stock Holding History

Stone House Investment Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.4K	Buy	+1,703	New	+$8.32K	﹤0.01%	382

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Stone House Investment Management's ABCL Position: Q2 2026 in Review

Stone House Investment Management opened a new position in AbCellera Biologics (ABCL) in Q2 2026: 1,703 shares worth $13.4K. The stake represents ﹤0.01% of the portfolio and ranks #382 among its holdings.

151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Stone House Investment Management held 1,703 shares of AbCellera Biologics worth $13.4K as of Q2 2026.
AbCellera Biologics was a new Stone House Investment Management position in Q2 2026.
AbCellera Biologics made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #382 holding.
151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.